{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:53:35Z","timestamp":1761486815299},"reference-count":14,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2000,6,1]],"date-time":"2000-06-01T00:00:00Z","timestamp":959817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Previous experiments with rifalazil (RLZ) (also known as KRM-1648) in combination with isoniazid (INH) demonstrated its potential for short-course treatment of\n            <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n            infection. In this study we investigated the minimum RLZ-INH treatment time required to eradicate\n            <jats:italic>M. tuberculosis<\/jats:italic>\n            in a murine model. RLZ-INH treatment for 6 weeks or longer led to a nonculturable state. Groups of mice treated in parallel were killed following an observation period to evaluate regrowth. RLZ-INH treatment for a minimum of 10 weeks was necessary to maintain a nonculturable state through the observation period. Pyrazinamide (PZA) was added to this regimen to determine whether the treatment duration could be further reduced. In this model, the addition of PZA did not shorten the duration of RLZ-INH treatment required to eradicate\n            <jats:italic>M. tuberculosis<\/jats:italic>\n            from mice. The addition of PZA reduced the number of mice in which regrowth occurred, although the reduction was not statistically significant.\n          <\/jats:p>","DOI":"10.1128\/aac.44.6.1458-1462.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"1458-1462","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of Rifalazil in Long-Term Treatment Regimens for Tuberculosis in Mice"],"prefix":"10.1128","volume":"44","author":[{"given":"Carolyn M.","family":"Shoen","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->State University of New York Upstate Medical University,1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon E.","family":"Chase","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Department of Medicine, Veterans Affairs Medical Center,2Syracuse, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"DeStefano","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->State University of New York Upstate Medical University,1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami S.","family":"Harpster","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Department of Medicine, Veterans Affairs Medical Center,2Syracuse, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex J.","family":"Chmielewski","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Department of Medicine, Veterans Affairs Medical Center,2Syracuse, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Cynamon","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->State University of New York Upstate Medical University,1 and"},{"name":"<!--label omitted: 2-->Department of Medicine, Veterans Affairs Medical Center,2Syracuse, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0007-0971(84)90165-7","article-title":"A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond.","volume":"78","author":"British Thoracic Society","year":"1984","unstructured":"British Thoracic Society A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br. J. Dis. Chest 78 1984 330 336","journal-title":"Br. J. Dis. Chest"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.3047"},{"key":"e_1_3_2_4_2","unstructured":"Daniel\n              W. W.\n          The Fisher exact test\n          Applied nonparametric statistics.\n          1978\n          110\n          114\n          Houghton Mifflin Co.\n          Boston Mass"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1378\/chest.76.6_Supplement.785","article-title":"The chemotherapy of pulmonary tuberculosis: a review.","volume":"76","author":"Fox W.","year":"1979","unstructured":"Fox W. The chemotherapy of pulmonary tuberculosis: a review. Chest 76 S 1979 785 796","journal-title":"Chest"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.5.9709072"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2809"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2245"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.298"},{"key":"e_1_3_2_10_2","first-page":"10","article-title":"How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.","volume":"2","author":"Mitchison D. A.","year":"1998","unstructured":"Mitchison D. A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2 1998 10 15","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0962-8479(96)90030-1","article-title":"Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL\/6 mice.","volume":"77","author":"Reddy M. V.","year":"1996","unstructured":"Reddy M. V. Luna-Herrera J. Daneluzzi D. Gangadharam P. R. J. Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL\/6 mice. Tubercle Lung Dis. 77 1996 154 159","journal-title":"Tubercle Lung Dis."},{"key":"e_1_3_2_12_2","first-page":"579","article-title":"Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.","volume":"119","author":"Singapore Tuberculosis Service\/British Medical Research Council","year":"1979","unstructured":"Singapore Tuberculosis Service\/British Medical Research Council Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. 119 1979 579 585","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_13_2","first-page":"265","article-title":"Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland.","volume":"125","author":"Snider D. E.","year":"1982","unstructured":"Snider D. E. Rogowski J. Zierski M. Bek E. Long M. W. Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland. Am. Rev. Respir. Dis. 125 1982 265 267","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_14_2","first-page":"1091","article-title":"Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.","volume":"130","author":"Snider D. E.","year":"1984","unstructured":"Snider D. E. Graczyk J. Bek E. Rogowski J. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am. Rev. Respir. Dis. 130 1984 1091 1094","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.426"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.6.1458-1462.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.6.1458-1462.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:47:46Z","timestamp":1645462066000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.6.1458-1462.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["10.1128\/AAC.44.6.1458-1462.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.6.1458-1462.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,6]]},"assertion":[{"value":"1999-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-03-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}